BWCS
CBIO

Beirne Wealth Consulting Services’s Crescent Biopharma CBIO Stock Holding History

Beirne Wealth Consulting Services’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$63K – 98
2023
Q1 		$63K Buy
500
+100
+25% +$22.5K 0.04% 96
2022
Q4 		$121K Buy
+400
New +$59K 0.06% 87

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Beirne Wealth Consulting Services's CBIO Position: Q2 2023 in Review

Beirne Wealth Consulting Services sold out of Crescent Biopharma (CBIO) in Q2 2023, closing a stake of 500 shares — an estimated $63K sold.

Beirne Wealth Consulting Services first reported a position in CBIO in Q4 2022 and held it in 2 quarters. The position peaked at $121K in Q4 2022. 55 funds tracked by Wall St. Rank hold CBIO as of Q2 2023.

  • Beirne Wealth Consulting Services reported no remaining Crescent Biopharma position as of Q2 2023 after selling out during the quarter.
  • Beirne Wealth Consulting Services sold 500 Crescent Biopharma shares in Q2 2023, an estimated $63K.
  • Beirne Wealth Consulting Services first reported a position in Crescent Biopharma in Q4 2022 and held it in 2 quarters.
  • Beirne Wealth Consulting Services's Crescent Biopharma position peaked at $121K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2023.

Based on Beirne Wealth Consulting Services's 13F filing for Q2 2023, filed 3 Aug 2023.